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Catechin and their derivatives have been studied to have antiviral potential against COVID-19 through in silico method “pharmacokinetics 
screening and molecular docking”. Pharmacokinetics and toxicity profiles were obtained through the ADMETSAR server and SwissADME 
server. Then proceed with the prediction of affinity through the method molecular docking using the software application MOE 2007.09. The test 
material is in the form of a 3D catechin structure and its derivatives as well as several control ligands downloaded via Pubmed. While template 
the Receptor Mpro protein and the Spike glycoprotein are downloaded from pdb.org (PDB ID: 6LU7 and 6LXT). The pharmacokinetic profile of 
catechins is relatively better than all control ligands with the lowest toxicity. Molecular docking results also show that catechins and their 
derivatives have a stronger affinity than control ligands. This research proves that catechin has antiviral potential through inhibition of Mpro 
protein and Spike glycoprotein COVID-19 virus. 
____________________________________________________________________________________________________________________ 




Penelitian ini bertujuan mengetahui potensi katekin dan turunannya sebagai antiviral COVID-19 secara in silico melalui metode skrining 
farmakokinetik dan docking molekuler. Profil farmakokinetika dan toksistas diperoleh melalui server ADMETSAR dan server SwissADME. 
Kemudian dilanjutkan dengan  prediksi afinitas  melalui metode docking moleculer menggunakan aplikasi software MOE 2007.09. Bahan uji 
berupa struktur 3D katekin dan turunannya serta beberapa ligan kontrol yang diunduh melalui Pubmed, sedangkan template reseptor Mpro 
protein dan spike glikoprotein diunduh dari pdb.org (PDB ID: 6LU7 dan 6LXT). Profil farmakokinetika katekin relatif lebih baik dibandingkan 
semua ligan kontrol dengan toksisitas terendah.  Hasil docking molekuler juga menunjukkan katekin dan turunannya memiliki afinitas lebih kuat 
dibanding ligan kontrol. Penelitian ini membuktikan katekin memiliki potensi sebagai antiviral melalui inhibisi Mpro protein dan Spike 
glikoprotein virus COVID-19. 
____________________________________________________________________________________________________________________ 





The presence of the new SARS-CoV2 coronavirus 
(COVID-19) in the Hubei-China province had become 
a global pandemic in early 2020 that almost paralyzed 
the whole world. The latest WHO release until on May 
3, 2020 shows the confirmed number of COVID-19 in 
the world has reached 3,349,786 infections with 
238,638 deaths. In Indonesia, the sufferers confirmed 
10,843 infections with 831 deaths (WHO, 2020). 
There is no effective therapy to overcome this viral 
infection, but various efforts continue. The use of 
antimalarial and antiviral compounds is one of the 
recommended uses. Use of chloroquine and remdesivir 
in vitro has been reported by Wang et al. (2020) and use 
of hydroxychloroquine in vitro has been reported by Liu 
et al. (2020) also ritonavir, ramdesivir, and favipiravir 
(De Clercq, 2019; Jin et al., 2019; Habibzadeh and 
Stoneman, 2020). However, the use of those compounds 
as antiviral COVID-19 in humans is still controversial 
both in terms of their effectiveness and side effects. 
This condition challenges researchers around the 
world to find more potential antiviral drug on COVID-
19 with minimal side effects. Digital screening of tens 
to thousands of compounds from the PubChem 
database was carried out by several researchers. The 
digital screening was carried out after several targets of 
COVID-19 protein were identified and the most 
commonly reported were M
pro
 protein and Spike 
glycoprotein COVID-19. M
pro
 protein is a main 
protease COVID-19 which has been successfully 
crystallized by Jin et al. (2020) and available in the 
protein database server www.pdb.org (PDB ID. 6LU7). 
The glycoprotein spike (PDB ID. 6LXT) was also 
successfully identified as Shang et al. (2020). The 
glycoprotein spike is shaped like nails that stick to the 
surface of the virus. The glycoprotein spike is believed 
to be a bridge of virus transmission into human cells 
(Xu et al., 2020) through strong binding affinity with 
ACE2, as a simulation model of biochemical 
interaction and crystal structure analysis reported by Li 
et al.  (2005). The glycoprotein spike has a high 
resemblance to the previous coronavirus, SARS-CoV. 
Among the potential compounds reported based on 
digital screening are hesperidin, kaempferol, 
naringenin, quersetin, catechins, and curcumin (Adem 
et al., 2020; Chen and Du, 2020; Khaerunnisa et al., 
2020; Trina et al., 2020; Utomo et al., 2020). 
Catechins and their derivatives are reported to be 
active as anti-oxidants, antihypertensives, anti-
Frengki et al. 
 
60 
inflammatory, antithrombogenic, and reduce fat content 
(Babu and Liu, 2008; Auclair et al., 2008). As an 
anticancer catechins and their derivatives have also 
been widely reported, even has reached the stage of 
clinical trials such as lung cancer (Wang et al., 2012), 
gastric cancer (Ju et al., 2005), skin cancer (Afaq et al., 
2003), and liver cancer (Jia et al., 2002). Potential 
antiviral in catechins contained in green tea plant 
extracts have also been reported by Xu et al. (2017). 
The green tea catechin has broad antiviral activity 
including hepatitis B virus (HBV), hepatitis C virus 
(HCV), Epstein-Barr virus (EBV), human 
immunodeficiency virus (HIV), dengue viruses, 
chikungunya virus (CHIKV) and Zika virus (ZIKV). It 
is hoped that catechins and their derivatives also have 
the potential to be antiviral on COVID-19. 
Although there are several reports that mention 
catechins to have antiviral potential on COVID-19, but 
the explanation is still limited to the results of digital 
screening as previous reports. The fact shows that 
catechin is a chiral compound with more than one 
spatial structure namely (-) - catechin [2R, 3S], (+) - 
catechin [2S, 3R], (-) - epicatechin [2R, 3R] and (+) - 
epicatechin [2S, 3S] (Cui et al., 2015). This was not 
explained in the report. Therefore, in addition to digital 
screening of suitable compounds as COVID-19 
antiviral candidates, the authors will also analyze the 
effect of stereoisomer differences on affinity and the 
ligand-receptor interaction model formed using the 
molecular docking method. The docking results will be 
supplemented with pharmacokinetic and toxicity 
profile data aimed at predicting the eligibility of 
candidates for the antiviral drug COVID-19 which is 
expected to work effectively and to consume safely. 
 
MATERIALS AND METHODS 
 
The ligand compounds used are (-) - catechin, (+) - 
catechin, (-) - epicatechin, (+) - epicatechin, (-) - 
catechin gallate, (+) - catechin gallate, catechin 3 '-O-
gallate, catechin 5-O-gallate, catechin 7-O-gallate, 
catechin 3'-glucoside, catechin 5-glucoside, hesperidin, 
chloroquine, hydroxychloroquine, redesivir, ritonavir, 
favipiravir obtained from the Pubchem database. 
Whereas the template for the COVID-19 M
pro 
protein 
and spike glycoprotein were downloaded from 
www.pdb.org (PDB ID: 6LU7 and 6LXT). 
  
Pharmacokinetic Prediction Test Ligands 
Pharmacokinetic profiles of all ligands use the 
ADME-Toxicity method and the parameters of drug 
likeness (Lipinski’s rules of five) through ADMETSAR 
server (http://lmmd.ecust.edu.cn:8000/predict/) and 
Swiss ADME server (http://www.swissadme.ch/index.php). 
 
Affinity Prediction  
A total of 11 download test ligands obtained from the 
Pubmed database and the receptors obtained from the 
protein database are prepared and optimized for their 3-
dimensional structure by adding hydrogen, eliminating 
water molecules, adding partial charges, minimizing 
energy and site binding is selected. Then docking is run 
using default MOE system at the binding site. Complex 
receptor-ligand is stored in the format of pdb, while the 
value of docking stored in format of mdb. The docking 
then visualized in the 3D structure via LigPlot using 
application software of MOE. While chiral ligands 
(catechin, epicatechin and catechin gallate) are designed 
in 2D and 3D structures through the help of ChemOffice 
software. Furthermore, it is prepared and optimized 
using MOE software as 11 ligands above. 
 
RESULTS AND DISCUSSION 
 
Prediction of Ligand Pharmacokinetic Profiles  
Each drug compound has physicochemical 
characteristics that affect its pharmacokinetic profile. 
The process of adsorption of compounds is influenced 
by several factors, such as lipophilicity, hydrogen 
bonds, molecular size, and pKa charge (Lawson et al., 
2013). Log P and Topological Polar Surface Area 
(TPSA) are parameters used to assess the adsorption 
power of a compound. Catechin, epicatechin, 
chloroquine, hydroxychloroquine, and favipiravir have 
log P <5 and TPSA <140 Å, so they have good 
adsorption ability. However, the absorption of 
catechins is thought to be lower than that of 
chloroquine, hydroxychloroquine, and favipiravir 
because catechins are Pgp protein substrates. Pgp 
protein in membrane protein acts as drugs efflux that 
functions to re-emerge compounds that enter the cell to 
the outside of cells so that the intracellular 
concentration of these compounds is low. Pgp is widely 
reported in the digestive system, especially in the 
intestine (Siddik, 2013). Catechin derivatives and other 
test compounds have a TPSA <140 Å, so that the value 
of human intestinal absorption is low. Nevertheless the 
predicted pharmacokinetic results of catechins and 
epicatechins still show high adsorption power.  
Catechins, epicatechin, and favipiravir do not 
interact with the cytochrome P450 enzymes (CYP2C9, 
CYP2D6 and CYP3A4), as well as catechin derivatives. 
Conversely chloroquine and hydroxychloroquine 
undergo metabolism by acting as a substrate or inhibitor 
of these metabolic enzymes. The metabolites produced 
are predicted to be pharmacologically inactive or even 
produce undesirable toxic effects. This estimation is 
proven by the higher chloroquine toxicity value, as well 
as hydroxychloroquine and favipiravir. In contrast, 
catechins, epicatechins. and their derivatives showed 
lower levels of toxicity. 
Data prediction of pharmacokinetic profiles and 
toxicity of all active compounds will be validated by 
Lipinski's Rules of Five. This is done to ensure the 
feasibility of potential compounds as candidates for 
drugs in humans. Characteristics of a good 
pharmacokinetic profile with low toxicity and 
compliance with Lipinski's rules of five, shows that 
catechin and epicatechin are very potential to be used 
as an alternative to antiviral COVID-19. Complete data 
on the predicted results of pharmacokinetic profiles and 
toxicity are shown in Table 1. 




The docking results show that all test and control 
ligands were able to interact to form complexes with 
receptors (M
pro
 protein and spike glycoprotein) 
COVID-19 virus. Interaction models of  ligand-
receptor are shown in Figure 1a and Figure 1b. All of 
them showed a tendency to release energy when 
forming complexes with the two receptors, but the 
strength of the affinity was different. The more 
negative the docking score obtained indicates its 
affinity with the receptor the stronger (Frengki et al., 
2019). 
Table 1. Results of prediction of pharmacokinetic parameters and druglieness (Lipinski's rules of five) ligands test 
 
Bbb= Blood brain barrier, Hib= Human Intestinal absorption, S/NS= Substrate/non substrate, C/NC= Carcinogen/non carcinogen,  I/NI= 
Inhibitor/non inhibitor, Aot= Acut oral toxicity 
 
 
Figure 1a. Interaction model of catechin 7-O-gallate (red), 
hydrocloroquine (yellow), and remdesivir (blue) to the main 
protease receptor Mpro COVID-19 (Pdb id. 6lu7) 
 
 
Figure 1b. Interaction model of catechin 5-O-gallate (red), 
hydrocloroquine (yellow), and remdesivir (blue) against 
COVID-19 glycoprotein spikes receptor (Pdb id. 6lxt) 
 





Figure 2. Stereoisomers of  (+/-) – catechin, -epicatechin, and -catechin gallate [2R, 3S] 
 
 
Figure 3a. 3D ligand conformation (-) - catechin [2R, 3S] (yellow) and (+) - catechin [2S, 3R] (red) when forming complexes 
with 6LU7 and 6LXT receptors 
 
 
Figure 3b. 3D ligand conformation (-) - epicatechin [2S, 3S] (yellow) and (+) - epicatechin [2R, 3R] (red) when forming 
complexes with 6LU7 and 6LXT receptors 
 
 
Figure 3c. 3D ligand conformation (-) - catechin gallate [2R, 3S] (yellow) and (+) - catechin gallate [2S, 3R] (red) when forming 
complexes with 6LU7 and 6LXT receptors 




Table 2. Free energy, number, and distance of hydrogen bonding from docking ligand with Mpro protein and spike glycoprotein 
 
Compounds 
Receptor main protease 
(Pdb ID. 6LU7) 
Receptor spike glycoprotein 
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Chloroquine -9.8398 Thr 243 2.84 -9.0316 No H-bond - 
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Catechins and some of their derivatives showed a 
stronger affinity for M
pro 
protein and glycoprotein 
spikes than hesperidin, chloroquine, hydroxyl-
chloroquine and some antivirals such as remdesivir, 
ritonavir, and favipiravir. This showed that catechins 
and their derivatives form a more stable ligand-receptor 
complex so that the potential for antiviral activity is 
thought to be stronger. Molecular docking results are 
shown in Table 2. 
Differences in stereoisomers of catechin, epicatechin, 
and catechin gallate (Figure 2) also cause differences in 
the strength of affinity for the two receptors above. The 
strength of successive affinities in the M"main 
protease"
pro
 protein receptor is catechin 7-O-gallate > 
catechin 5-O-gallate > catechin 3'-O-gallate > (-)-
catechin  > (+)- catechin gallate > (-)-epicatechin> (+)-
catechin > (-)-catechin gallate > catechin 3'-glucoside > 
(+)-epicatechin > catechin 5-glucoside > hesperidin > 
hydrocloroquine > remdesivir > chloroquine > ritonavir 
> favipiravir. Meanwhile, glycoprotein spike is (+)-
catechin gallate > (-)-catechin gallate > catechin 7-O-
gallate > catechin 3'-O-gallate > (-)-epicatechin > 
catechin 5-O-gallate > (+)-epicatechin > (-)-catechin > 
hesperidin > catechin 5-glucoside > catechin 3'-
glucoside > (+)-catechin > hydroxychloroquine > 
remdesivir > ritonavir > favipiravir. 
Khairunnisa et al. (2020) reported that catechins 
and some potential flavonoid derivatives have been 
developed as antiviral COVID-19, which supported the 
result of the present research, although there are 
differences in the selection of binding site. Khairunnisa 
et al. (2020) traced binding site based on the native 
ligand of M
pro 
protein, while this study preferred 
binding site to search for system default MOE 
software. In addition, this study also optimized 
catechins based on differences in spatial structure into 4 
different stereoisomers [(-)- catechin, (+)- catechin), (-
)- epicatechin and (+) - epicatechin], as well as gallate 
catechins to 2 stereoisomer [(-)- catechin gallate and 
(+)- catechin gallate)]. The results of the analysis based 
on this stereoisomer reference are believed to be more 
valid. 
The stereoisomer [2R, 3S] conformation of catechin 
gives a distinct affinity stronger than the conformation 
of [2S, 3R] with an affinity of -14.1370 kcal/mol and -
13.5387 kcal/mol respectively for M
pro
 protein. Similar 
results occur in interactions between catechin and 
glycoprotein spike receptors. The affinity of catechin 
with [2R, 3S] conformation also shows the release of 
energy of -11,322 kcal/mol compared to catechins with 
[2S, 3R] conformation which shows the release of 
energy of -10.4993 kcal/mol. 
Conformation of [2S, 3S] on epicatechin also gives 
a stronger affinity than conformation of [2R, 3R] with 
an affinity of -13.6338 kcal/mol and -12.2790 kcal/mol 
respectively for M
pro
 proteinSimilar results also occur 
in interactions between catechins and glycoprotein 
spike receptors. The affinity of epicatechin with 
conformation [2S, 3S] also shows the release of energy 
of -11.5055 kcal/mol compared to epicatechin with 
[2R, 3R] conformation which shows the release of 
energy of -10.32292 kcal/mol. The hydroxyl (OH) 
group in the 3S position has a very important role in 
increasing the affinity of catechins and epicatechins in 
the two receptors above. 
On the other hand, the addition of a galloyl group in 
the 3S position shows a lower affinity compared to the 
3R position galloyl group. This is observed in 
conformation (-)- catechin gallate [2R, 3S] which gives 
an affinity value of -12.9942 kcal/mol weaker than 
conformation (+)- catechin gallate [2S, 3R] which gives 
an affinity value of -13.7186 kcal/mole. This was 
observed in M
pro 
protein. Likewise in the glycoprotein 
spike the addition of galloyl groups at position 3S 
shows a weaker affinity compared to position 3R. This 
is observed in conformation (-)- catechin gallate [2R, 
3S] giving an affinity value of -12.4199 kcal/mol 
slightly weaker than conformation (+) - catechin gallate 
[2S, 3R] which gives an affinity value of -13.0183 
kcal/mole. In Figure 3c, a catechin gallate B ring shift 
is observed away from the site binding Mpro protein or 
spike glycoprotein, thus the B ring shift also determines 
the change in affinity besides the presence of hydroxyl 
(OH) groups in the 3S position. While catechins and 
epicatechin still in Figures 3a and 3b still show the 





Catechins and their derivates show a better 
pharmacokinetic profile with lower toxicity and also 
show a docking score stronger compared to 
chloroquine and other antiviral control. Research In 
silico is able to explain the potential of catechins as an 
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